GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GlucoTrack Inc.
GlucoTrack is developing a non-invasive glucometer. Its stock price is betting on a revolution in diabetes treatment. The price chart reflects high volatility and reliance on clinical trial results and FDA approval, which could change the lives of millions of people.
Share prices of companies in the market segment - Therapeutic medical equipment
GlucoTrack develops non-invasive devices for monitoring blood glucose levels in people with diabetes, aiming to replace traditional fingersticks. We've classified it as "Therapeutic Medical Equipment." The chart below shows how the market is evaluating new diabetes treatment technologies.
Broad Market Index - GURU.Markets
GlucoTrack is a medical device company developing non-invasive blood glucose monitoring systems for people with diabetes. Its innovations have earned it a spot on the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the medical device sector.
Change in the price of a company, segment, and market as a whole per day
GCTK - Daily change in the company's share price GlucoTrack Inc.
For GlucoTrack, Inc., a developer of non-invasive glucose meters, daily volatility reflects sensitivity to news about clinical trials and FDA approvals. This metric is an important element for analyzing companies in the diabetes care sector.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
GlucoTrack develops non-invasive blood glucose monitoring devices. The diabetes medical equipment sector is highly competitive and innovative. The chart below shows the average volatility in this niche, allowing you to compare GCTK's performance with other market players.
Daily change in the price of a broad market stock, index - GURU.Markets
GlucoTrack develops non-invasive glucometers. This innovative medical technology company's stock reflects the hopes of millions of people for a more convenient way to manage diabetes. Its high volatility stems from the risks and prospects of breakthrough medical technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GlucoTrack Inc.
GlucoTrack, Inc.'s year-over-year performance is a story about the development of a noninvasive glucometer. Its 12-month market cap depends entirely on progress toward FDA approval for its earlobe-attached device. Success could be a true revolution for millions of diabetics, eliminating the need for finger pricking.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
GlucoTrack, Inc. develops noninvasive glucose monitoring systems. Its technology has the potential to revolutionize diabetes treatment. Its stock price is highly volatile, reflecting investor confidence in its breakthrough potential and ability to commercialize its technology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GlucoTrack develops non-invasive glucometers that could free millions of people with diabetes from finger pricking. Its year-over-year market capitalization is a testament to the anticipation of a technological breakthrough. A successful launch of such a product could make the company a leader in a multi-billion-dollar industry.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GlucoTrack Inc.
GlucoTrack develops non-invasive glucometers. Being in the approval stage, its monthly pricing is dependent on news. Progress with the FDA and clinical trial data are the main events shaping expectations.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. This is a potentially revolutionary product for millions of diabetics. The company's success depends entirely on the accuracy and approval of its device. The medical device sector's performance reflects the enormous interest in innovations in diabetes treatment.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GlucoTrack is developing a non-invasive glucometer. It's one of the most coveted technologies in diabetes treatment. The company's shares move not with the market, but in anticipation of a technological breakthrough. Any news about development progress or regulatory approval could trigger explosive growth, ignoring any macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GlucoTrack Inc.
GlucoTrack is developing a non-invasive glucometer, a "holy grail" for millions of people with diabetes. Its weekly stock price reflects progress in clinical trials and news on the road to FDA approval. Success here could be a game-changer for the market.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
GlucoTrack develops non-invasive blood glucose monitoring systems for people with diabetes. The company's success depends on the accuracy of its technology and regulatory approval. The chart shows how its stock reacts to news compared to medical device giants.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GlucoTrack develops non-invasive glucometers. This is a breakthrough technology, and its shares are highly sensitive to news about its accuracy and regulatory approvals. The chart will show how much its performance is detached from the broader market and driven by investor confidence in its unique product.
Market capitalization of the company, segment and market as a whole
GCTK - Market capitalization of the company GlucoTrack Inc.
GlucoTrack's market capitalization chart reflects investors' assessment of its years-long quest to create a noninvasive glucometer. Its dynamics tell the story of the hopes and disappointments surrounding the development of its earlobe-attached device. Its current low valuation reflects market skepticism after a long journey without a commercial product.
GCTK - Share of the company's market capitalization GlucoTrack Inc. within the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer for people with diabetes. The company's market share in the medical device sector is small, but it's targeting the "holy grail" of diabetology. Its capitalization is a bet on its technology, which could eliminate the need for finger pricking.
Market capitalization of the market segment - Therapeutic medical equipment
This chart shows the total market capitalization of the entire therapeutic medical equipment market. For GlucoTrack, which is developing a non-invasive glucometer, this line represents a sign of hope for diabetics. The chart's growth reflects the enormous need for more convenient ways to monitor blood sugar, the "Holy Grail" of the diabetes market.
Market capitalization of all companies included in a broad market index - GURU.Markets
GlucoTrack is developing a non-invasive blood glucose monitor for people with diabetes. Its market capitalization is the valuation of the dream of millions—measuring blood sugar without pricking a finger. This market share represents the struggle to make life more comfortable for people with diabetes.
Book value capitalization of the company, segment and market as a whole
GCTK - Book value capitalization of the company GlucoTrack Inc.
GlucoTrack is developing a noninvasive blood glucose monitor. Its book value is its scientific and financial capital. It consists of patents for the technology and funds for its refinement and launch. How has this capital changed in anticipation of a breakthrough? The chart below shows this story.
GCTK - Share of the company's book capitalization GlucoTrack Inc. within the market segment - Therapeutic medical equipment
GlucoTrack, Inc. develops non-invasive glucometers. Its technology requires a substantial infrastructure: R&D centers for sensor development and production lines for assembling these complex medical devices. The chart shows its share of the physical infrastructure needed to create the next generation of medical technology.
Market segment balance sheet capitalization - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer. The medical equipment sector, as the chart shows, is capital-intensive. GlucoTrack is an innovator. Its capital is invested in R&D and production of a unique device that could change the lives of diabetics.
Book value of all companies included in the broad market index - GURU.Markets
GlucoTrack's assets are not drugs, but rather manufacturing facilities for a non-invasive glucometer that measures blood sugar levels by attaching to the earlobe, without pricking a finger. The book value reflects the industrial potential of this long-awaited device for diabetics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GlucoTrack Inc.
GlucoTrack is developing a non-invasive glucometer. Its market capitalization reflects its chances of creating the "Holy Grail" for diabetics. It's a bet on a technological breakthrough that could change the lives of hundreds of millions of people.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer. It's the holy grail of diabetes treatment. Its high valuation on this chart is a bet that its technology will prove accurate and be approved, opening up a multi-billion dollar market, despite the high risk of failure.
Market to book capitalization ratio for the market as a whole
GlucoTrack is developing non-invasive glucometers, which could be a breakthrough for millions of diabetics. The company's market value reflects the potential of this technology to transform a vast market. This chart shows how investors value companies focused on solving global medical problems and the premium they place on this potential.
Debts of the company, segment and market as a whole
GCTK - Company debts GlucoTrack Inc.
GlucoTrack develops non-invasive glucose monitoring systems. The company requires significant capital to conduct large-scale clinical trials and obtain regulatory approval. This graph illustrates the long and expensive path to commercialization of a breakthrough but complex medical device.
Market segment debts - Therapeutic medical equipment
GlucoTrack is a company developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. The development of such a device is considered the "holy grail" of diabetes treatment. The chart shows how the company is funding its lengthy and expensive R&D and clinical trials to prove the accuracy and reliability of its technology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GlucoTrack Inc.
GlucoTrack is developing a non-invasive blood glucose monitor for people with diabetes. Bringing such a complex medical device to market is a lengthy and extremely capital-intensive process. This chart illustrates how heavily the company relies on debt to fund its R&D, clinical trials, and regulatory approvals.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
GlucoTrack is developing a noninvasive blood glucose monitor for people with diabetes. This is a huge market, but a technologically complex challenge. This chart shows how the company is funding its expensive R&D. It compares its debt load to the market capitalization of the entire medical device sector, reflecting its financial risks.
Debt to book value of all companies in the market
GlucoTrack is developing a non-invasive blood glucose monitor. The development and certification of such a medical device is a lengthy and extremely expensive process. How heavily does the company rely on debt financing? This graph of total debt in the economy helps assess the riskiness of its financial model as it seeks breakthrough success.
P/E of the company, segment and market as a whole
P/E - GlucoTrack Inc.
GlucoTrack (formerly Integrity Applications) is developing a non-invasive blood glucose meter. This chart shows investor expectations over the years. The valuation soars on news of development progress and falls on delays, reflecting the complexity of creating such a device.
P/E of the market segment - Therapeutic medical equipment
GlucoTrack, Inc. is a medical technology company developing a non-invasive blood glucose monitor for people with diabetes that doesn't require a finger prick. This chart illustrates the average valuation in the therapeutic medical device sector, where investors are betting on breakthrough technologies that could dramatically improve the lives of millions of patients.
P/E of the market as a whole
GlucoTrack, Inc., formerly Integrity Applications, develops a non-invasive blood glucose monitoring device that doesn't require a finger prick. This chart reflects the overall sentiment in the medical technology sector. It helps us understand whether GCTK's high valuation stems from faith in its revolutionary diabetes technology or is part of general industry optimism.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GlucoTrack Inc.
GlucoTrack, Inc. is developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. The company's success depends on the accuracy and approval of this device. This chart illustrates the investors' confidence in the company's potential to revolutionize diabetes care by offering a painless alternative to millions of patients.
%20P%2FE%20GlucoTrack%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GlucoTrack-Inc.&v=1772573693703 "Chart of the company's future (projected) P/E GlucoTrack Inc.")
Future (projected) P/E of the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. This could be a revolution for millions of diabetics. The graph shows average profitability expectations in the sector, helping to understand the market's confidence in the commercial success of this long-awaited technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772573693709 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
GlucoTrack, Inc. is developing a non-invasive glucometer for people with diabetes that measures blood sugar levels without pricking a finger. It's a potentially revolutionary product. This chart of overall market sentiment shows how willing investors are to fund companies that have the potential to create a breakthrough product for a huge market, but carry high technological risks.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772573693768 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GlucoTrack Inc.
GlucoTrack, Inc. (formerly Integrity Applications) is developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. The company's profitability depends on the successful launch of this product. This chart shows the long and costly journey to developing a revolutionary medical device for millions of diabetics.
Profit of companies in the market segment - Therapeutic medical equipment
GlucoTrack, Inc. is developing a non-invasive blood glucose monitor that doesn't require fingersticks, which could dramatically change the lives of people with diabetes. This chart shows the overall profitability of the therapeutic medical device sector, where creating more convenient and painless devices for chronically ill patients has enormous market potential.
Overall market profit
GlucoTrack, Inc. develops non-invasive blood glucose monitoring systems for people with diabetes. The need for more convenient diabetes management methods is enormous and unaffected by economic cycles. The company's success is determined by technological breakthroughs and market acceptance, not by the macroeconomic situation, as illustrated by this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GlucoTrack Inc.
GlucoTrack is developing a noninvasive blood glucose monitor for people with diabetes. The company's future profitability depends on the successful launch of this long-awaited product and its accuracy. This graph reflects the enormous hopes and high risks associated with creating the "holy grail" of diabetes treatment.
%20profit%20of%20the%20company%20GlucoTrack%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GlucoTrack-Inc.&v=1772573693949 "Graph of future (projected) profit of the company GlucoTrack Inc.")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer that measures blood sugar levels without pricking a finger. This device could dramatically change the lives of millions of people with diabetes. The company's success depends on obtaining approvals. This chart shows revenue expectations for the therapeutic medical device sector, helping to assess the potential of this technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772573693971 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
GlucoTrack, Inc. develops noninvasive blood glucose monitoring devices. The company's success depends on product approvals and commercialization. This economic outlook impacts the overall solvency of the healthcare system and the willingness of patients and insurers to pay for innovative medical devices.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772573694028 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GlucoTrack Inc.
GlucoTrack is developing a non-invasive glucometer for people with diabetes. Revenue will depend on the successful launch of this long-awaited product. This chart reflects the high expectations of investors. Its significance reflects the company's bet on achieving a breakthrough in diabetes management.
P/S market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer that allows people with diabetes to measure their blood sugar levels without pricking their fingers. This device could revolutionize the lives of millions of patients, making diabetes management painless and convenient. This chart shows the average revenue estimate for the sector, helping to assess the potential of this breakthrough technology.
P/S of the market as a whole
GlucoTrack is developing a non-invasive glucometer for people with diabetes that measures blood sugar levels without pricking a finger. This chart helps us understand the enormous premium investors are willing to pay for a technology that could solve a major problem for millions of people, even if commercialization hasn't yet begun.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GlucoTrack Inc.
GlucoTrack is developing a non-invasive blood glucose monitor for people with diabetes that doesn't require fingersticks. For a company with such a potentially breakthrough technology, valuation based on future revenue is key. It reflects investors' high expectations that this product will change the lives of millions of people and capture a significant share of the diabetes management market.
%20P%2FS%20GlucoTrack%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GlucoTrack-Inc.&v=1772573694436 "The graph of the company's future (projected) P/S GlucoTrack Inc.")
Future (projected) P/S of the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive blood glucose monitor for people with diabetes that doesn't require fingersticks. This chart compares the company's estimated future revenue with other medical device manufacturers. It reflects investor expectations regarding the commercial success of this long-awaited device and its potential to transform the lives of diabetics.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772573694474 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
GlucoTrack is developing a non-invasive blood glucose monitor that measures blood glucose levels without pricking a finger. The company's success depends on the device's accuracy and its acceptance by the diabetes community. This graph of overall investor expectations reflects the enormous hope for technology that can improve the quality of life for millions of people with diabetes.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772573694542 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GlucoTrack Inc.
This chart shows the revenue of GlucoTrack, Inc., a company developing a noninvasive glucose meter for people with diabetes. Revenue may be modest during the product launch phase. Future growth will depend directly on regulatory approvals and successful commercialization of this long-awaited technology.
Sales of companies in the market segment - Therapeutic medical equipment
GlucoTrack, Inc. (formerly Integrity Applications) is developing a non-invasive glucometer for people with diabetes. While the company is in the development and approval stages, it does not yet have significant revenue. Future sales will depend on the successful commercialization of this long-awaited technology, which could eliminate the need for finger pricking.
Overall market sales
GlucoTrack, Inc. is developing a non-invasive blood glucose monitor for people with diabetes. The company aims to eliminate the need for painful finger pricks. This overall economic outlook doesn't diminish the enormous need for more convenient diabetes management solutions, which is GlucoTrack's primary driver.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GlucoTrack Inc.
GlucoTrack (formerly Integrity Applications) is developing a noninvasive glucose meter for people with diabetes. The company's future revenue depends entirely on the successful commercialization of this device and its acceptance by patients and doctors. This chart shows analyst sales forecasts, reflecting their belief in the revolutionary potential of noninvasive glucose monitoring.
%20sales%20of%20the%20company%20GlucoTrack%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GlucoTrack-Inc.&v=1772573694753 "Schedule of future (projected) sales of the company GlucoTrack Inc.")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
GlucoTrack, Inc. is developing a noninvasive blood glucose monitor for people with diabetes. This chart shows the forecast for the diabetes treatment device market. Is demand for more convenient and painless glucose monitoring methods growing? This reflects the overall trend toward improving patients' quality of life.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772573694795 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
GlucoTrack develops non-invasive blood glucose monitoring devices for people with diabetes. Demand for these innovative medical devices is driven by their accuracy, convenience, and insurance coverage. While this overall economic activity may influence consumers' willingness to pay for new devices, the primary driver is clinical need.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772573694852 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GlucoTrack Inc.
GlucoTrack (formerly Integrity Applications) is developing a noninvasive blood glucose monitor for people with diabetes. This chart shows the company's long and challenging path to commercialization. Profitability depends on regulatory approvals, the accuracy and reliability of the technology, and its ability to compete with existing monitoring methods.
Market segment marginality - Therapeutic medical equipment
GlucoTrack, Inc. (formerly Integrity Applications) is developing a noninvasive glucometer for people with diabetes. The company's profitability depends on successful completion of the development, obtaining regulatory approvals worldwide, and its ability to compete with traditional glucose measurement methods. This graph illustrates the complex path to commercialization of a breakthrough medical technology.
Market marginality as a whole
GlucoTrack, Inc. develops non-invasive blood glucose monitoring devices for people with diabetes. The company aims to disrupt a market dominated by invasive methods. This gross margin chart reflects the state of the medical device industry and the healthcare system's readiness to embrace disruptive, but potentially expensive, technologies.
Employees in the company, segment and market as a whole
Number of employees in the company GlucoTrack Inc.
GlucoTrack is developing a noninvasive glucometer for people with diabetes. Its team of engineers and scientists is key to creating this complex device. This chart shows how the company is investing in personnel to complete product development, conduct clinical trials, and obtain regulatory approvals in the US and Europe, a lengthy and expensive process.
Share of the company's employees GlucoTrack Inc. within the market segment - Therapeutic medical equipment
GlucoTrack is developing a non-invasive glucometer for people with diabetes. Creating such a complex medical device requires years of work by a team of engineers, physicists, and clinical trial specialists. This chart shows the company's market share, reflecting the scale of its R&D efforts and the stage of product development.
Number of employees in the market segment - Therapeutic medical equipment
GlucoTrack, Inc. is developing a noninvasive glucometer that measures blood sugar levels without pricking a finger. This graph shows employment in the therapeutic medical device sector. This device could radically change the lives of millions of people with diabetes, making glucose monitoring painless and more convenient.
Number of employees in the market as a whole
GlucoTrack develops noninvasive blood glucose monitoring systems for people with diabetes. The company's growth depends on the success of its technology and its market acceptance. This chart shows the big picture, and GlucoTrack exemplifies how medical technologies aimed at improving the quality of life of millions of people are creating new high-tech jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GlucoTrack Inc. (GCTK)
GlucoTrack, Inc. is developing a noninvasive glucose monitoring system for people with diabetes. This is a breakthrough technology in medical technology. This chart demonstrates the market's high expectations. It reflects the high market value per engineer, which is a bet on the success of their R&D and their ability to transform the diabetes diagnostics market.
%20of%20the%20company%20GlucoTrack%20Inc.%20(GCTK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GlucoTrack-Inc.-GCTK&v=1772573695288 "Chart of market capitalization per employee (in thousands of dollars) of the company GlucoTrack Inc. (GCTK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
GlucoTrack (GCTK) is developing a non-invasive blood glucose monitor for people with diabetes. In the medical device industry, this measurement represents the potential to change the lives of millions. The astronomically high employee salary may be due to the development of the "holy grail" of diabetology—a device that measures blood sugar without pricking a finger.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772573695314 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
GlucoTrack is developing a non-invasive glucometer for people with diabetes. In the medical device sector, this is the "holy grail." The chart shows a high valuation per employee, as the market understands that a successful product in this area will be a global blockbuster. The market cap reflects hope for a technological breakthrough, not current sales.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772573695380 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GlucoTrack Inc. (GCTK)
GlucoTrack (formerly Integrity Applications) is developing a non-invasive glucometer. This medical device requires extensive R&D. This graph shows the company's current stage. A negative loss per employee is typical for the R&D phase, reflecting the costs of engineers and physicians until FDA/CE approval is achieved.
%20Chart%20GlucoTrack%20Inc.%20(GCTK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GlucoTrack-Inc.-GCTK&v=1772573695411 "Company Profit Per Employee (in thousands of dollars) Chart GlucoTrack Inc. (GCTK)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
GlucoTrack, Inc. (formerly Integrity Applications) develops non-invasive blood glucose monitoring devices. In the field of medical gadgets for chronic diseases, the efficiency per employee indicates the commercial potential of the technology. The graph demonstrates how successfully the team can turn an innovative development into a profitable mass-market product.
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772573695494 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
GlucoTrack (GCTK) is a company developing a non-invasive glucometer—a device that measures blood sugar without pricking a finger. It's a medtech R&D company targeting the vast diabetes market. This chart helps understand how the R&D model, where engineers and scientists work on a single "breakthrough" product, compares to the average market performance of its staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772573695577 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GlucoTrack Inc. (GCTK)
GlucoTrack (GCTK) develops non-invasive glucometers. This chart shows the path to commercialization of their breakthrough technology. A sharp increase in revenue per employee will signal the market success of a device that could change the lives of millions of diabetics and generate huge profits for a small team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GlucoTrack-Inc.-GCTK&v=1772573695634 "Sales chart per company employee GlucoTrack Inc. (GCTK)")
Sales per employee in the market segment - Therapeutic medical equipment
GlucoTrack (GCTK) (formerly Integrity Applications) is developing a noninvasive glucometer—a device for measuring blood glucose levels without pricking a finger. It's a medtech company in the R&D/commercialization stage. This chart shows the average output in the sector. For GCTK, this is an indicator of how productive their R&D and future sales are compared to the giants.
Sales per employee for the market as a whole
GlucoTrack (GCTK) is a company developing a noninvasive glucose monitor for people with diabetes. Their goal is to replace finger pricks. Currently, their focus is on R&D and clinical trials. This graph reflects their pre-commercial status: all efforts by the engineering team are focused on finalizing and approving the device.
Short shares by company, segment and market as a whole
Shares shorted by company GlucoTrack Inc. (GCTK)
GlucoTrack (GCTK) is developing a non-invasive (no finger-prick) glucometer. It's the "holy grail" for diabetics, something giants have been trying to achieve for decades. This chart tracks short positions. The shorts reflect high skepticism: investors are betting that GCTK's technology, like so many before it, will prove inaccurate.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GlucoTrack-Inc.-GCTK&v=1772573695736 "Short Shares Chart for the Company GlucoTrack Inc. (GCTK)")
Shares shorted by market segment - Therapeutic medical equipment
GlucoTrack (GCTK) is developing a non-invasive (no finger prick required) blood glucose monitor for people with diabetes. This chart shows the overall shortfall in the medical device sector. It demonstrates investor skepticism about this "sacred" goal, where many have failed due to accuracy issues.
Shares shorted by the overall market
GlucoTrack is developing non-invasive glucometers, challenging the giants. This chart illustrates the overall market pessimism. When investors are afraid, they don't believe in "Davids"; they bet on "Goliaths." Fear makes them doubt that a small R&D company has the capital to withstand a war with industry titans.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GlucoTrack Inc. (GCTK)
GlucoTrack is developing a non-invasive glucometer. It's the "holy grail" for diabetics, and expectations are high. This graph measures the "pulse" of these hopes. It "overheats" on any news about technological advances and just as quickly "cools" on information about delays or the need for additional testing.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GlucoTrack-Inc.-GCTK&v=1772573695748 "RSI 14 indicator chart for the company's stock GlucoTrack Inc. (GCTK)")
RSI 14 Market Segment - Therapeutic medical equipment
GlucoTrack (GCTK) is working on the "holy grail" of diabetes treatment—a non-invasive glucose monitor that doesn't require needles. It's a highly speculative bet. This chart measures the collective "pulse" of the entire Therapeutic Equipment sector. It helps investors understand whether GCTK's performance reflects their data or whether the entire industry is overheated or oversold by the overall trend.
RSI 14 for the overall market
For GlucoTrack, a medical equipment company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GCTK (GlucoTrack Inc.)
GlucoTrack (GCTK) is a company striving to create the "holy grail" for diabetics: a non-invasive (no puncture) glucose monitor using ultrasound and RF. This chart shows the highly speculative average price target from analysts, which depends almost entirely on their belief in the success of FDA trials and the commercialization of this device.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GCTK-GlucoTrack-Inc.&v=1772573695818 "A chart showing analyst consensus forecasts for the expected stock price. GCTK (GlucoTrack Inc.)")
The difference between the consensus estimate and the actual stock price GCTK (GlucoTrack Inc.)
GlucoTrack (GCTK) is another company chasing the "Holy Grail" of diabetes: a non-invasive glucometer that measures blood sugar without pricking a finger. This chart shows the difference between the market valuation and the consensus forecast. It reveals whether experts believe their technology (an ear clip) will finally work.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GCTK-GlucoTrack-Inc.&v=1772573695849 "A chart showing the difference between the consensus forecast and the actual stock price. GCTK (GlucoTrack Inc.)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
GlucoTrack (GCTK) is an Israeli company developing a non-invasive (no needle required) ear clip glucose meter for diabetics. It's the "Holy Grail" for millions of patients. This chart shows the overall expectations for the therapeutic medical device sector. It reflects how confident experts are in this technology.
Analysts' consensus forecast for the overall market share price
GlucoTrack is an Israeli company that has been developing a non-invasive (puncture-free) glucometer for diabetics for years. It's the "holy grail" of diagnostics. This chart shows the overall "risk appetite" in the market. For GCTK, whose value is an option on a technological breakthrough, overall market optimism (risk appetite) is critical for investor confidence and R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GlucoTrack Inc.
GlucoTrack (GCTK) is an R&D company that has been struggling for decades to achieve the Holy Grail of diabetes: a non-invasive (non-puncture) glucose monitor. Their signature device is an ear clip that uses ultrasound and electromagnetic waves. This chart is a summary of their endless R&D. It reflects their (constant) failures in clinical trials and their race to keep up with the money.
AKIMA Market Segment Index - Therapeutic medical equipment
GlucoTrack (GCTK) aims to revolutionize diabetes treatment by creating a puncture-free glucometer. The company is developing a non-invasive system (an ear clip) that uses ultrasound and electromagnetic waves to measure glucose levels without using a single drop of blood. This graph shows the average index for the segment, helping to assess how this holy grail technology compares to the average.
The AKIM Index for the overall market
GlucoTrack is a MedTech company developing implantable continuous glucose monitoring (CGM) devices. This chart, which reflects the market average, is a backdrop. It helps assess how GCTK, which is striving to compete in the diabetes market, stacks up against overall macroeconomic trends.
